Angel Invest Boston

Why Sal Is Bullish on Biotech VeraMorph has a new way to deliver insoluble drugs by mouth. Founder Doug Godfrin, PhD elucidates the promise of accessing the 85% of drugs that are not soluble. Does VeraMorph pass Sal Daher’s screen for angel-scale biotech? Listen and find out. Sponsors: Purdue University entrepreneurship and Peter Fasse, patent attorney at Fish and Richardson Highlights: Sal Daher, CFA Introduces Doug Godfrin, PhD, Founder of VeraMorph A New Way to Deliver Drugs Orally How VeraMorph Gets Around the Solubility Problem VeraMorph’s Approach Is Janus-like: Shelf Stable but Available Where Needed The Decade of Biotech & VeraMorph AltrixBio: Gastric Bypass Surgery in a Pill Sal Daher’s Biotech Screen: Strong Patents “VeraMorph actually owns the patents outright for this platform technology.” “We've really taken a totally different perspective with this class of material by focusing on immediate release via oral delivery...” Sal Daher’s Biotech Screen: Capable Academic Founder Sal Daher’s Biote